Sign up to save your podcasts
Or
Share Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?
In the latest episode of Pathfinders, Senior Biotechnology Analyst Gregory Renza discusses what’s driving the latest spate of biotech M&A activity — the new players and partnership dynamics that are creating what he calls “a landscape of competition” in the broader market.
View all episodes
By RBC Capital Markets
5
1212 ratings
In the latest episode of Pathfinders, Senior Biotechnology Analyst Gregory Renza discusses what’s driving the latest spate of biotech M&A activity — the new players and partnership dynamics that are creating what he calls “a landscape of competition” in the broader market.
More shows like Pathfinders in Biopharma
View all
Pardon My Take
81,748 Listeners
The Daily
112,758 Listeners
Up First from NPR
56,140 Listeners
The Readout Loud
314 Listeners
Making Sense
57 Listeners
Biotech 2050 Podcast
60 Listeners
Business Of Biotech
84 Listeners
BioCentury This Week
27 Listeners
RBC's Markets in Motion
39 Listeners
Biotech Hangout
9 Listeners
Industries in Motion
10 Listeners
Powering Sustainable Ideas
0 Listeners
Macro Minutes
1 Listeners
Strategic Alternatives
17 Listeners
Goldman Sachs The Markets
76 Listeners
The BioCentury Show
11 Listeners